Londong W, Londong V, Cederberg C, Steffen H
Gastroenterology. 1983 Dec;85(6):1373-8.
In a placebo-controlled, double-blind, crossover, and randomized trial, the effect of 30, 60, and 90 mg of oral omeprazole on peptone-stimulated gastric acid secretion and synchronously measured gastrin release was studied in 8 healthy subjects. Peptone-stimulated acid output was reduced dose-dependently by 42%, 80%, and 92%, respectively. In spite of a short mean plasma half-life of 52 min, the inhibitory effect lasted for greater than 4.5 h and was significantly correlated to the area under the plasma concentration time curve for omeprazole. Mean basal serum gastrin and gastrin profiles increased insignificantly without alteration of integrated gastrin output and did not show any correlation either to the omeprazole area under the plasma concentration time curve or to the inhibition of peptone-stimulated acid secretion. Side effects, significant alterations of laboratory screen, or alterations of serum concentrations of thyroid hormones were not detected. In conclusion, omeprazole is a potent and, under the conditions tested, well-tolerated inhibitor of meal-stimulated gastric acid secretion in humans.
在一项安慰剂对照、双盲、交叉和随机试验中，对8名健康受试者研究了30毫克、60毫克和90毫克口服奥美拉唑对蛋白胨刺激的胃酸分泌以及同步测量的胃泌素释放的影响。蛋白胨刺激的酸排出量分别以剂量依赖性方式降低了42%、80%和92%。尽管平均血浆半衰期较短，为52分钟，但抑制作用持续超过4.5小时，并且与奥美拉唑的血浆浓度时间曲线下面积显著相关。平均基础血清胃泌素和胃泌素曲线无明显增加，整合胃泌素排出量无改变，并且与奥美拉唑的血浆浓度时间曲线下面积或蛋白胨刺激的胃酸分泌抑制均无相关性。未检测到副作用、实验室筛查的显著改变或甲状腺激素血清浓度的改变。总之，在测试条件下，奥美拉唑是一种强效且耐受性良好的人餐刺激胃酸分泌抑制剂。
